skip to Main Content
Dr Barbara Pacchetti as Chief Scientific Officer and Dr Mikael Sodergren as Research Director


Recognised scientific pioneers to drive research and innovation to shape the global future of medicinal cannabis

EMMAC, the European independent medical cannabis company, is pleased to announce the appointment of two internationally acclaimed scientific leaders to its Board and Leadership team. Dr Barbara Pacchetti has been appointed Chief Scientific Officer joining the Board and will spearhead EMMAC’s commitment to developing the highest quality cannabis product research and innovation globally. Dr Mikael Sodergren, a world-respected academic clinician, will join EMMAC’s leadership team with the pivotal role of overseeing research projects designed to shape the future of medical cannabis therapeutics.

Prior to joining EMMAC, Dr Pacchetti held the position of Scientific Affairs Manager at Linnea, a manufacturer of Botanical extracts and pharmaceutical ingredients of natural origin for use in the pharmaceutical, nutraceutical and cosmetic industries.

Antonio Costanzo, CEO of EMMAC, commented: “I am delighted to welcome both Dr Pacchetti and Dr Sodergren to the EMMAC team. Barbara is one of the most experienced research scientists in Europe with over four years experience specific to the research and development and process technology of cannabis. Her unique skillset, experience and expertise will be invaluable to EMMAC as we focus on bringing the highest quality cannabis products to market.”

Dr Barbara Pacchetti, Chief Scientific Officer at EMMAC, commented: “I am very pleased to be joining the EMMAC team at such an exciting time for the company and the cannabis industry as a whole. I look forward to leading a skilled team to drive a research and development programme designed to build the best-in-class knowledge on cannabinoids and to create innovative pharma or nutritional solutions. One of the big challenges in the growing market of cannabis is guaranteeing the highest quality and a proper product design; EMMAC is committed to ensuring the upmost in quality and design for medicinal and healthcare users.”

Commenting on Dr Sodergren’s appointment Costanzo continued: “Mikael is an internationally recognised academic clinician, speaking extensively in Europe and the US in relation to cancer. He shares our vision and believes in the potential benefits of cannabis for his patients. The research programme he will lead reflects a shared commitment to backing up this belief with real data and science.”

Dr Mikael Sodergren, Research Director of EMMAC and academic clinician at Imperial College London, commented: “I am delighted to join EMMAC and lead a research programme designed to gain a greater understanding of the therapeutic properties of cannabis for a range of clinical conditions. I am looking forward to developing a broad research programme ranging from pre-clinical laboratory work to evaluating the clinical efficacy of cannabis-derived medicinal products in patients.” 


EMMAC Life Sciences PLC is the European independent medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production. With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.




      Catriona Flint

Senior Associate

      D +44 (0)20 7466 5113

      M +44 (0)7766 030 687

      E [email protected]


107 Cheapside, London, EC2V 6DN

T +44 (0)20 7466 5000  W


This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

What Must Be Done To Enact Germany’s New Cannabis Law And What Will Its Adult-Use Market Look Like?

With Germany’s Government-in-waiting set to deliver adult-use cannabis, BusinessCann explores the delivery challenges and how the legislation may be shaped. BACK in 2015 the German Green Party published its Cannabis Control Act (CCA). Although it made no progress in the Bundestag at the time, it is now emerging as the blueprint for the creation of…

ESG and Cannabis is No Easy Task Right Now

by Hilary Bricken, Principal Harris Bricken Socially responsible and “sustainable” investing is picking up in popularity across retail and institutional investors alike. According to Wikipedia, “[i]n less than 20 years, the ESG movement has grown from a corporate social responsibility initiative launched by the United Nations into a global phenomenon representing more than US$30 trillion…

Who Needs a License? New York Weed Dispensaries Are Already Opening

Stores that offer recreational marijuana might not be entirely legal yet, but entrepreneurs are ready to start righting the wrongs of the war on drugs list prices, per se, but “Suggested Donations,” starting at $20. The packages offered in return are thank you “gifts.” “We don’t sell anything,” says one register operator at Uncle Budd’s…

Germany’s incoming government unveils plans to legalize cannabis

Three German political parties have sealed a deal for a new government, with left-leaning Olaf Scholz the proposed next chancellor following lengthy coalition negotiations and a historic election that sees Angela Merkel stepping down after 16 years at the helm. The incoming government’s vision for Germany includes plans to legalize cannabis. It also aims to…

More Categories

Back To Top
×Close search